2月27日 - ** 医疗技术公司Lensar LNSR.O股价在下午交易中上涨28.8%，至12.20美元
** 根据LSEG汇编的数据，受益于白内障手术技术系统ALLY，公司第四季度营收为1670万美元，高于分析师预计的1490万美元。
** 公司第四季度每股净亏损1.61美元，高于预期的18美分
** 预计第一季度收入增长将与2024年的增长率保持一致
** 过去12个月，LNSR增长了94
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.